A First-in-human Study of KT502 Administered Subcutaneously to Adult Participants With Rheumatoid Arthritis (RA)

NCT07564154 · clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
27
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Kali Therapeutics, Inc.